Hyfe, founded in 2020, has rapidly established itself as a pioneer in the realm of AI-powered cough-monitoring technology. Positioned at the forefront of precision medicine for respiratory health, their patented machine-learning software facilitates passive and long-term tracking of cough frequency. This innovative approach yields new health insights, crucial for both clinical advancements and patient care optimization.
Renowned for powering 50+ clinical studies, Hyfe's solutions significantly benefit pharmaceutical enterprises and academic researchers aiming to enhance clinical trials. Their technology is an asset for healthcare providers focused on optimizing chronic cough management, and it bolsters digital therapeutics in transforming respiratory illness care.
Their last known investment was a Convertible Note on 01 February 2021, led by Plug and Play. With a headquarters in the United States and active collaboration with global pharma leaders and premier academic bodies, Hyfe is well-positioned to expand its impact in the AI, Health Care, and Machine Learning sectors.